

Structure-based discovery of pyrazolobenzothiazine derivatives as inhibitors of hepatitis C virus replication

Maria Letizia Barreca, Giuseppe Manfroni, Pieter LEYSEN, Johan Winkvist, Neerja Kaushik-Basu, Jan Paeshuyse, Ramalingam Krishnan, Nunzio iraci, Stefano Sabatini, Oriana Tabarrini, Amartya Basu, U. Helena Danielson, Johan Neyts, and Violetta Cecchetti

J. Med. Chem., **Just Accepted Manuscript** • DOI: 10.1021/jm301643a • Publication Date (Web): 14 Feb 2013

Downloaded from <http://pubs.acs.org> on February 17, 2013

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



ACS Publications
High quality. High impact.

Structure-based discovery of pyrazolobenzothiazine derivatives as inhibitors of hepatitis C virus replication

Maria Letizia Barreca,^{,†} Giuseppe Manfroni,^{*,†} Pieter Leyssen,[‡] Johan Winquist,[#] Neerja Kaushik-Basu,[§] Jan Paeshuyse,[‡] Ramalingam Krishnan,[§] Nunzio Iraci,[†] Stefano Sabatini,[†] Oriana Tabarrini,[†] Amartya Basu,[§] U. Helena Danielson,[#] Johan Neyts,[‡] and Violetta Cecchetti[†]*

[†]Dipartimento di Chimica e Tecnologia del Farmaco, Sezione di Chimica Farmaceutica II,
Università degli Studi di Perugia, Via del Liceo 1, 06123 Perugia, Italy

[‡]Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium

[#]Department of Chemistry – BMC, Uppsala University, Box 576, SE-751 23 Uppsala, Sweden.

[§]Department of Biochemistry and Molecular Biology UMDNJ-New Jersey Medical School 185
South Orange Avenue, New Jersey 07103, USA

Abstract

The NS5B RNA-dependent RNA polymerase is an attractive target for the development of novel and selective inhibitors of hepatitis C virus replication. In order to identify novel structural hits as anti-HCV agents, we performed structure-based virtual screening of our *in-house* library followed by rational drug design, organic synthesis and biological testing. These studies led to the identification of pyrazolobenzothiazine scaffold as a suitable template for obtaining novel anti-HCV agents targeting the NS5B polymerase. The best compound of this series was the *meta*-fluoro-*N*-1-phenyl pyrazolobenzothiazine derivative **4a**, which exhibited an EC_{50} = 3.6 μ M, EC_{90} = 25.6 μ M and CC_{50} > 180 μ M in the Huh 9-13 replicon system, thus providing a good starting point for further hit evolution.

Keywords. Hepatitis C virus, RNA-dependent RNA polymerase, structure-based drug discovery, virtual screening, NS5B inhibitors, pyrazolobenzothiazines.

Introduction

Hepatitis C virus (HCV) is a small, enveloped RNA virus that belongs to the Flaviviridae family. Worldwide, over 170 million people have become chronically infected with HCV;¹ the overall prevalence is ~3%, with rates up to 20%, for example in Egypt.² The virus may remain undetected for >15 years, a period during which transmission can occur. Due to intensive donor screening, transfusion-associated cases have become very rare, and most of the new infections can be attributed to high risk drug-related behavior (60%) and unsafe injection practices. Following a usually mild and subclinical acute infection, a chronic stage develops in 70-85% of the cases.² Chronic HCV infection is one of the leading causes of liver cirrhosis and hepatocellular carcinoma (primary liver cancer), and the first indication for liver transplantation in industrialized countries.³

The standard treatment of HCV infection used to be a regimen of pegylated interferon alpha (pegIFN- α) in combination with ribavirin (RBV). During treatment, a high number of patients suffer from severe adverse effects and the sustained viral response rate unfortunately is rather low for individuals infected with genotype 1, the most prevalent genotype in North America, Europe and Asia. Recently, the first two direct-acting antiviral agents (DAAs) targeting the NS3/4A protease, telaprevir and boceprevir, have been approved by the Food and Drug Administration and European Medicines Agency for the treatment of patients infected with HCV genotype 1.⁴ Any of these two drugs, combined with pegIFN- α and RBV in a triple combination therapy, induce a significantly improved sustained virological response rate both in treatment-naïve patients as well as those that have a treatment history.⁵ However, despite improved response rates, combination treatment including either boceprevir or telaprevir shows long-term toxic effects, is associated with high costs, results in an increased pill burden on the patient, suffers from many drug interactions, and has a low barrier to resistance if used as monotherapy.⁵ Therefore, there is still a need for alternative treatment options, which are preferably pegIFN- α and RBV-free and which target multiple steps of the virus replication cycle or different sites on a viral protein. In principle, every step of the HCV lifecycle, from receptor binding and endocytosis, to fusion, uncoating, translation, polyprotein processing, RNA replication, virion assembly, maturation, transport and release, can be a target for the development of new and selective anti-HCV drugs.⁶

Since the elucidation of the molecular genetics of the virus, the non-structural HCV proteins NS3/4A protease and NS5B polymerase have drawn most attention as drug targets. In contrast to the protease, drugs targeting the NS5B polymerase have yet to reach the market. NS5B is a RNA-dependent-RNA polymerase which catalyzes the synthesis of progeny viral RNA strands, and because of its apparent sequence and structural difference with human DNA and RNA polymerases, poses an attractive target for the development of selective inhibitors.^{7,8} To date, a variety of nucleoside and non-nucleoside HCV polymerase inhibitors have been reported.^{9,10} The non-

nucleoside inhibitors (NNIs) can be divided into five groups based on the distinct allosteric binding site on the HCV polymerase they target, namely thumb site I (TSI), thumb site II, (TSII), palm site I (PSI), palm site II (PSII), and palm site III (PSIII).¹¹ Because of the number of drugable pockets on NS5B and the lack of cross-resistance between inhibitors that target these different binding sites, multiple NS5B-targeting drugs may likely become part of future combination therapy. For many of these pockets, protein-ligand crystal structures, together with biochemical evidence, are described in literature, thus offering a solid base to set up exploratory projects aimed at identifying novel anti-NS5B chemotypes.

In continuation of our efforts towards identification of new chemical entities that inhibit HCV replication,^{12,13} in this study we have focused our attention on the allosteric PSI, located at the junction of the thumb and palm domains and in close proximity to the active site. Several chemotypes that bind at this site have been reported in literature,^{10,11} among them, hydroxyquinoline-benzothiadiazine (BTDZ) and hydroxyquinoline-benzothiazine (BTZ) classes represented by derivatives **1** and **2**, respectively (Figure 1), are the most investigated PSI-NNIs with promising candidates in clinical development.¹⁴




Figure 1. Chemical structures of **1** and **2** as representative of BTDZ and BTZ PSI-NNIs, respectively.

Given the scenario of PSI-NNIs as highly effective antiviral agents, we herein describe the rational design, synthesis, anti-NS5B activity and inhibitory effect on HCV replication of novel pyrazolobenzothiazine-based compounds in a quest to discover new selective anti-HCV agents.

Results and Discussion

Structure-based identification of the pyrazolobenzothiazine scaffold

The first goal of this study was to investigate in-depth the binding requirements for potent NS5B inhibitory activity at PSI. This aspect was important to gain useful information regarding the identification of new potential PSI-NNIs. Towards this, we focused our attention on the BTDZ and BTZ classes (*e.g.*, compounds **1** and **2**) (Figure 1) which, beside being potent inhibitors in both NS5B polymerase and cellular replicon system assays, are well characterized from the structure-activity relationships (SAR) standpoint.¹⁴ Several studies have reported detailed structural analysis of the ligand/NS5B contacts for different inhibitors of the BTDZ and BTZ series.¹⁴ All these inhibitors share similar contacts with the NS5B residues, although the more potent compounds establish some additional hydrogen bond interactions. Of note, all of the available X-ray structures reveal some highly conserved water molecules which mediate the protein-inhibitor hydrogen-bond interactions.

Using as reference the co-crystal structure of NS5B with compound **2**,¹⁵ we have summarized the key binding requirements as follows (Figure 2): *i*) a hydrophobic group (HYD-1) occupying a pocket mainly defined by residues Met414, Gly410, Gln446, Asn411 and Tyr415; *ii*) a *N*-alkyl/aryl lipophilic tail (HYD-2) filling a deep pocket shaped by Tyr448, Cys366, Pro197, Tyr415, Leu384, Arg200 and Ser368; *iii*) a hydrogen bond acceptor group (HBA-1) involved in a direct interaction with the backbone N-H of Tyr448 and in a water-mediated interaction with Gly449; *iv*) one of the sulfone oxygens of the BTZ/BTDZ moiety (HBA-2) establishing a water-mediated interaction with

Ser556 or Ser288; *v*) the phenyl portion of the benzothiadiazine ring system (ETF) making an edge-to-face aromatic interaction with Phe193; and *vi*) the methylsulfonamide group (HBD-HBA) making strong interactions with Asn291 and Asp318. Moreover, one of the sulfonamide oxygen atoms of the methylsulfonamide moiety forms a third H-bond network with residue Ser288 via the structural water molecule mentioned in point *iv*.




Figure 2. Schematic representation of the interactions between NS5B polymerase and compound **2** (PDB ID 3G86) as representative of BTZ/BTDZ inhibitors. NS5B residues lying within a distance of 4 Å from the bound ligand are shown and color coded as follows: red-acidic; green-hydrophobic; purple-basic; cyan-polar; white-Gly. Waters are displayed as gray circles, while interactions between ligand atoms and protein residues are marked with lines: solid pink, H-bonds to the protein backbone; dotted pink, H-bonds to protein side chains; green, π - π stacking interactions. The six chemical features of PSI-NNIs are highlighted as well: HBA, hydrogen bond acceptor; HBD, hydrogen bond donor; HYD, hydrophobic regions; ETF, group involved in edge-to-face interaction.

Taking into account the above observations, structure-based drug discovery (SBDD) approaches were performed to discover novel anti-NS5B chemotypes from an *in-house* library of 2692 molecules synthesized and/or published by our research group. The compound collection was prepared for docking using the LigPrep process¹⁶ and submitted to a structure-based virtual screening workflow against the crystal structure of NS5B in complex with inhibitor **2** (PDB ID 3G86) by means of the Glide software.¹⁷ All water molecules found in the crystal structure were removed, with the exception of the conserved water molecules involved in direct interactions with the ligand (Figure 2). In order to validate the docking performance, test calculations using **2** were carried out, extracting the ligand from the corresponding NS5B complex and then docking it back into the allosteric pocket of the enzyme crystal structure. The best docking pose of **2** (XP GScore = -9.4 kcal/mol) agreed well with its experimental binding conformation, with a root-mean square (rms) deviation value of 0.3 Å.

The top-ranked compounds were visually inspected searching for virtual hits endowed with high docking score and also able to create the key interactions with the PSI residues. Unfortunately, none of the *in-house* compounds possessed both these characteristics. However, our attention was attracted by the pyrazolobenzothiazine-3-carboxymethyl ester derivative **3a**¹⁸ (rank position #94, XP GScore = -5.8 kcal/mol) (Figure 3), a compound already reported by our research group as an intermediate in the preparation of anti-inflammatory agents.¹⁹




Figure 3. A) Simplified 2D representation of the predicted interactions between compound **3a** and NS5B amino acids (color legend as in Figure 2). B) Docking pose of compound **3a** (green) together with the experimental position of BTZ derivative **2** (violet). Water molecules are displayed in cyan, whereas hydrogen bonds are represented as yellow dashed lines. Both pictures show protein residues within 4 Å of the docked compound.

Interestingly, compound **3a** was predicted to bind in a fashion somewhat similar to that of known PSI-NNIs (Figure 3), establishing some of the already mentioned key ligand-NS5B interactions (Figure 2). The sulfonyl function of the molecule, corresponding to the HBA-1 feature, was engaged in a direct hydrogen bonding interaction with Tyr448; the same moiety also established a water-mediated interaction with Gly449. The previously described hydrophobic features HYD-1 and HYD-2, were represented here by the phenyl ring of the pyrazolobenzothiazine nucleus and the N-phenyl tail, respectively. Of note, the pyrazole ring showed an additional π - π interaction with the side chain of Tyr448.

Computer-driven design of pyrazolobenzothiazine derivatives

The interaction between compound **3a** and NS5B polymerase was evaluated using surface plasmon resonance (SPR), while its effect on the catalytic activity of the enzyme was determined in a functional assay and its effect on transcription was evaluated in a cell-based HCV subgenomic replicon system. The analysis of the interaction with NS5B (Con-1 strain, genotype 1b) indicated that the affinity was very low with a dissociation equilibrium constant $K_D > 300 \mu\text{M}$. In the functional anti-NS5B (CA21, genotype 1b) assay, $50 \mu\text{M}$ of the compound resulted in 11% inhibition. A preliminary screening analysis for its ability to inhibit HCV replication (genotype 1b), using a HCV subgenomic replicon containing human hepatoma cells (Huh 5-2), showed that compound **3a** exhibited ~40% inhibition of HCV RNA replication at non-toxic concentration. Albeit the modest biological results obtained for **3a** did not allow to classify it as hit, the interesting information raised from the proposed binding conformation suggested that this chemotype was worthy of further optimization. Therefore, taking into account the key chemical features of PSI-NNIs (Figure 2), we planned suitable chemical modifications of derivative **3a** with the objective of obtaining potent NS5B small-molecule inhibitors.

Since it was not straight forward to synthesize molecules possessing the six desired features at the same time, we decided to design a series of pyrazolobenzothiazine-based compounds (**4a-j**, **5a** and **6a**), (Scheme 1 and Table 1) which could potentially contain all the binding requirements except HBA-2. In particular, superimposition of the docked conformation of compound **3a** on the BTZ inhibitor 2-NS5B co-crystal structure (Figure 3) suggested replacement of methyl with *para*-methanesulphonamidephenyl moiety from the C-3 carboxylic group. Thus, derivative **4a** was designed where the ester linkage was replaced by the more chemically stable amide bridge.

Starting from compound **4a**, the deep hydrophobic cavity occupied by the chemical feature HYD-2 was explored by moving the fluorine atom from *meta* to *ortho* (**4b**) and *para* (**4c**) positions, or by designing the unsubstituted N-1 phenyl derivative **4d**. The fluorine atom was also replaced with

strong electron withdrawing (*i.e.* NO₂, **4e-g**) or electron donating (*i.e.* NH₂, **4h-j**) substituents. Finally, the methanesulphonamide group was substituted by an amino group obtaining compound **5a**. This change was aimed at assessing the impact of the mesyl moiety in this series of compounds. Finally, the direct optimized version of compound **3a**, where the methyl fragment of the C-3 carboxylic group was substituted by the *para*-methanesulphonamidophenyl moiety, was also planned (**6a**).

Before starting with the chemical synthesis of the new pyrazolobenzothiazine-based compounds, we sought to validate our hypothesis by performing automated docking studies of the designed derivatives using the computational protocol described above. The docking results predicted that **4a-j**, **5a** and **6a** may potentially interact with the NS5B residues of PSI in a fashion similar to known NNIs, as discussed below. For instance, the proposed binding mode of pyrazolobenzothiazine derivative **4a** (XP GScore = -7.4 kcal/mol) is shown in Figure 4, where a schematic representation of the predicted NS5B-compound **4a** interactions is also illustrated.




Figure 4. A) Schematic representation of the predicted interactions between compounds **4a** and the NS5B residues (color legend as in Figure 2). B) Docked conformation of compound **4a** (green) together with the X-ray conformation of BTZ derivative **2** (violet). Water molecules are displayed

in cyan, while hydrogen bonds are represented as yellow dashed lines. Both figures illustrated NS5B residues lying within a distance of 4 Å from the docked compound.

Beside the ligand-NS5B interactions already highlighted for the parent compound **3a** (Figure 3), derivative **4a** was able to establish the additional desired π - π (EFT) and three-point (HBD-HBA) interactions through its *para*-methanesulphonamide phenyl group, in agreement with the SBDD. Further, since NS5B harbors multiple allosteric sites, we next investigated the binding mode of the rationally designed pyrazolobenzothiazine derivatives at the other pockets. For this purpose, molecular docking studies at PSII (PDB ID 3FQL),²⁰ PSIII (PDB ID 3LKH),²¹ TSI (PDB ID 2BRK)^{12b,22} and TSII (PDB ID 3FRZ)^{12b,23} were performed. At first, the ability of the docking setup to reproduce the co-crystallized pose of each inhibitor within the respective NS5B site was validated. The pyrazolobenzothiazine derivatives were then docked into the allosteric pockets, and the visual inspection of the results revealed their inability to properly occupy those binding sites.

Together, this data suggested that the newly designed compounds **4a-j**, **5a** and **6a** may bind at PSI, thus providing a rationale to synthesize and test these molecules as potential inhibitors of NS5B polymerase and HCV replication.

Synthesis of pyrazolobenzothiazine derivatives

The synthetic route employed for the preparation of targets compounds **4a-j**, **5a** and **6a** is depicted in Scheme 1. Starting from key intermediate **7**,¹⁹ the pyrazolobenzothiazine-3-carboxymethyl esters **3a**,¹⁹ **8b-c**, **8d**,¹⁹ **8e-g** were prepared by condensation with the appropriate commercially available phenylhydrazines hydrochloride, in MeOH at reflux. According to our previous works^{19,24} this reaction led to the formation of the sole N-1 phenylpyrazolobenzothiazine regioisomers. In fact, in all ¹H NMR spectra of derivatives **3a**, and **8b-g** the presence of H-9 proton shielded by the anisotropic effect of N-1 phenyl ring is a proof consistency of the assigned

structure. In order to unambiguously demonstrate the reaction regioselectivity, a bidimensional NOESY spectrum was performed for derivative **8e**, as an exhaustive example. The results indicated two diagnostic interactions: the first one was observed between the H-9 proton of pyrazolobenzothiazine nucleus and the H-2' proton of the N-1 phenyl ring whereas the second one occurred between the same H-9 proton and the H-4' proton (Figure 5). No interactions were found between the N-1 phenyl ring and the C-3 methyl ester.

The esters intermediates **3a**,¹⁹ and **8b-g** were hydrolyzed under basic conditions at reflux to give the pyrazolobenzothiazine-3-carboxylates **9a-c**, **9d**,¹⁹ and **9e-g**. They were then converted in the corresponding carbonyl chloride, under reflux of SOCl₂, and immediately reacted with *N*-(4-aminophenyl)methanesulfonamide,²⁵ using Et₃N as scavenger, to afford the target amide derivatives **4a-g**. On the other hand, nitro derivatives **4e-g** were reduced to the corresponding amino targets **4h-j** employing H₂ flux and Raney-Ni as catalyst.

Using the same procedures, the carbonyl chloride of **9a** was reacted with *N*-(4-hydroxyphenyl)methanesulfonamide²⁶ to give the target ester derivative **6a**; intermediate **9a** was also converted into amino derivative **5a** by reaction with 4-nitroaniline followed by catalytic reduction with H₂/Raney-Ni.





Figure 5. NOESY experiments for **8e** showing two main interactions: H-9→H-2' and H-9→H-4'.

Scheme 1^a



^aReagents and conditions: (i) $\text{ArNHNH}_2 \cdot \text{HCl}$, MeOH, reflux; (ii) 10% aq NaOH, MeOH, reflux; (iii) a) SOCl_2 , reflux; b) ArNH_2 or ArOH , Et_3N , dry DMF, 40 °C; (iv) H_2 , Raney-Ni, DMF, rt, atm pressure.

Biochemical and biological studies

The synthesized compounds **4a-j**, **5a** and **6a** were evaluated by a combination of three biochemical and biological methods to determine the binding affinity for NS5B polymerase, the ability to inhibit the enzyme and the anti-HCV activity. The SPR biosensor analysis is a direct binding method that provides information on the interaction between the compounds and the enzyme; the affinity is an important SAR characteristic, but does not provide the functional

information that is obtained from the enzyme activity-based inhibition or replicon assays. The latter is the most complex assay of the three, providing a measure not only of effects on polymerase activity but other features related to viral replication. Ideally, a good compound shows a low K_D , IC_{50} and EC_{50} values. In recent years, ligand efficiency indices have been shown to be useful tools in reviewing the potency data, where potency is either a measure of binding (K_D) or biological activity (K_i , IC_{50} or EC_{50}). Ligand efficiency (LE)²⁷ refers to the potency of a compound averaged by its non-hydrogen atom count and is used to try to avoid unnecessary increases in molecular weight as a lever to increase potency. Although LE is probably the most widely used and intuitive metric, it does not take into account lipophilicity. Considering the crucial role of lipophilicity in drug discovery, the concept of ligand-lipophilic efficiency (LLE or LipE) has recently become a popular measure linking potency and lipophilicity in an attempt to estimate druglikeness.²⁸ For a given compound, LLE is defined as pPotency – logP or logD, where pPotency is $-\log(\text{Potency})$, logP is the octanol/water partition coefficient and logD is the distribution coefficient. LogP value of a substance is most appropriate for neutral (un-ionized) compounds, while logD (the pH-dependent lipophilicity descriptor) should be used when working with ionizable compounds. Since our pyrazolobenzothiazines did not contain a functionality likely to be ionized at the pH of the used assays, logP value was chosen as the relevant parameter. In this study, LLE values were calculated to support the SAR understanding and to evaluate the druglikeness of the compounds by employing logP calculated using the program QikProp (see also Supporting Information Table 1S).²⁹

These data are reported in Table 1.

SPR interaction analysis.

The interaction between the synthesized compounds and HCV-NS5B genotype 1b was assayed using a SPR-based biosensor as reported in Experimental Section.

No compounds were found to affect the immobilized enzyme irreversibly or linger in the instrument flow system to potentially interfere with subsequent measurements. An appropriate level of structural integrity and functionality of the detection surface was maintained throughout the experiments, as determined by injections of a positive control substance (filibuvir, PF00868554).²³

The apparent affinities were determined for all compounds except two, *i.e.* **4c** and **4g**. The results from derivative **4c** suggested that this compound might interact with the enzyme, but possible solubility issue prevented a proper determination of the affinity. On the other hand, there was no detectable interaction between compound **4g** and the target.

Starting from pyrazolobenzothiazine **3a**, the introduction of the *para*-methanesulphonamidephenyl moiety at the C-3 position permitted an increased affinity to be observed for almost all the synthesized compounds (K_D values ranged from 14 to 165 μ M and corresponding LLE parameters from 0.99 to 3.41). In particular, the analogues bearing an amide or ester linkage (compounds **4a** and **6a**, respectively) exhibited increased NS5B affinity when compared to the parent compound **3a**. Deletion of the methansulfonyl fragment negatively affected the binding affinity, as highlighted by comparing both K_D and LLE values of derivative **4a** (K_D = 75 μ M, LLE = 1.85) and **5a** (K_D = 161 μ M and LLE = 0.99). Both these observations were in agreement with the rationale of our design. NS5B affinity was also influenced by the position of the substituent on the N-1 phenyl ring. Indeed, SPR data combined with lipophilic efficiency index analysis revealed that in the fluoro and nitro subsets, the *meta* substitution (**4a** and **4e**) was preferred over the *ortho* substitution (**4b** and **4f**). In particular, *meta*-nitro N-1-phenyl derivative **4e** (K_D = 14 μ M and LLE = 3.41) displayed both the best affinity and LLE value within this pyrazolobenzothiazine series.

NS5B polymerase assay.

The anti-NS5B RdRp activity of all the synthesized compounds was evaluated by the standard primer-dependent elongation reaction employing poly rA/U₁₂ template-primer and recombinant

HCV NS5B Δ 21 according to previously described procedures.³⁰ Compound **1**³¹ was included as a reference NS5B inhibitor and yielded an IC₅₀ value of 0.085 \pm 0.006 μ M, consistent with previously reported data.³² All compounds were first screened at 50 μ M concentration to identify NS5B inhibitor candidates exhibiting \geq 50% inhibition of NS5B RdRp activity at this concentration. This investigation led to the identification of eight compounds (**4a-4d**, **4f**, **4g**, **4i** and **4j**) satisfying this criterion, while four compounds (**4e**, **4h**, **5a** and **6a**) exhibited, at the same concentration, ~21-46% inhibition of NS5B RdRp activity. The eight selected compounds were further screened for their NS5B inhibition potency and yielded IC₅₀ values ranging from 3.9 μ M to 40 μ M, with corresponding LLE values ranging from 2.4 to 3.8 (Table 1). The enzymatic data, in agreement with the SPR analysis, thus highlighted that the rational introduction of the *para*-methanesulphonamidephenyl moiety at the C-3 position was a valid strategy to increase the inhibitory activity of the starting compound **3a**; which did not reach 50% inhibition but only showed 11% inhibition at 50 μ M. Furthermore, the enzyme inhibition results, similarly to that observed by the SPR data analysis, clearly showed how the deletion of the methansulfonyl resulted detrimental in this series of pyrazolonbenzothiazines (compare **4a** with an IC₅₀ value of 21 μ M versus **5a** with 31.5% inhibition at 50 μ M).

Looking at both the NS5B inhibition data and LLE values, further considerations can be proposed. The position of the substituent on the N-1 phenyl ring influenced the anti-NS5B activity. In particular, in this series the substitution at the *para* position (**4c**, **4g** and **4j**) was preferred over the *ortho* (**4b**, **4f** and **4i**) and *meta* (**4a**, **4e** and **4h**) positions. For instance, *para*-fluoro N-1-phenyl pyrazolobenzothiazine **4c** displayed the most potent activity in this series with an IC₅₀ of 3.9 μ M and LLE of 3.11, while its *ortho* (**4b**) and *meta* (**4a**) analogues showed IC₅₀ of 14.2 μ M and 21 μ M, and LLE of 2.66 and 2.40, respectively. These data clearly suggest that, although our compounds exhibited lower anti-NS5B potency compared to the representative BTMZ **1**, the

pyrazolonbenzothiazine nucleus merits further investigation representing a new chemical scaffold unrelated to any known class of NS5B NNIs.

Anti-HCV activity.

The selective antiviral activity of the target compounds (**4a-j**, **5a**, and **6a**) was evaluated in the HCV genotype 1b subgenomic replicon system (Huh 5-2). From the dose-response curves, the concentration of the compound that inhibits virus replication by 50% (*i.e.*, EC₅₀) as well as the concentration of compound that reduces host cell metabolism by 50% (*i.e.*, CC₅₀) was derived. These values in turn allowed us to calculate the selectivity index (*i.e.*, SI = CC₅₀/EC₅₀), a measure for the therapeutic potential of the compound in the assay system (Table 1).

A preliminary analysis of the data obtained from the replicon assay apparently showed that, with the exception of derivatives **4g**, **4h**, and **4j**, the pyrazolobenzothiazines herein reported did not possess any significant cytotoxicity. Furthermore, the nontoxic compounds were able to inhibit HCV replication in a micromolar range.

However, even though an EC₅₀ may be obtained from the dose-response curve, following interpretation of the dose-response curve, compounds were only considered as selective inhibitors in the replicon assay when significant inhibition (>70%) of virus RNA replication was observed at concentrations that did not exert an adverse effect on host cell metabolism. The antiviral response observed for the compounds that did not match these criteria most likely had to be attributed to a pleiotropic or aspecific effect of the compound on the host cell metabolism. In addition, the cell and monolayer morphology of the selected compounds was checked microscopically, as the microtiter plate readout data did not necessarily allow to identify minor changes that can be detected visually. Even though the dose-response curves (data not shown) of several compounds (derivatives **4a-c** and **5a**) matched the hit selection criteria, following microscopic inspection, it was apparent that the compounds induced changes at the level of cell and monolayer morphology. Even though these

1
2
3 observations pointed towards an aspecific or pleiotropic effect being responsible for the observed
4 anti-HCV activity, it however cannot be excluded from this assay that the compounds in addition
5 did not inhibit HCV replication as well.
6
7

8
9 Taking into account the above general considerations, some preliminary SAR can be proposed. A
10 good activity coupled with no apparent cytotoxic effects was maintained within the N-1-
11 fluorophenyl subset, with compound **4a** being the most interesting derivative ($EC_{50} = 7.5 \mu M$) since
12 notably it was also able to reach 90% inhibition of HCV replication at non-toxic concentration
13 ($EC_{90} = 42 \mu M$). To better evaluate compound **4a** as true anti-HCV agent, it was validated at the
14 level of viral RNA replication in the Huh 9-13 replicon system by means of real-time quantitative
15 RT-PCR. In this assay, derivative **4a** showed a selective antiviral effect ($EC_{50} = 3.6 \mu M$; $EC_{90} =$
16 $25.6 \mu M$) without any cytostatic effect ($CC_{50} > 180 \mu M$, $SI > 50$). A dose-response curve matching
17 the hit selection criteria was obtained, suggesting selective anti-HCV activity. However, based on
18 the microscopic observations, no final conclusion can be drawn.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33


34 **Highlights from the LLE analysis**













35
36 The introduction of the concept of LE has been useful as it provides a measure of the binding
37 energy of the ligand per atom. This has been extended to also account for lipophilic contributions,
38 in the LLE metric. The magnitude of LLE is thought to be correlated with druggability and it can be
39 used to select and prioritize compounds with high affinity per atom and low lipophilicity. The new
40 pyrazolobenzothiazine derivatives were therefore evaluated using this metric. The LLE calculated
41 from K_D and IC_{50} values was useful for ranking and identified compounds **4e** (3.4) and **4g** (3.80) as
42 the ones with the highest LLE, respectively (see also Supporting Information Figure S1 and S2).
43 These results can be compared to the calculated mean LLE values for a large and diverse data set
44 representing different stages of drug discovery recently published by Tarcsay *et al.*³³ Although LLE
45 greater than 5 is usually considered optimal for a promising drug candidate, LLE values of 2.5 were
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

found for both fragment and HTS hits, while fragment and HTS leads showed higher values of 3.9 and 3.6, respectively. The study further reported LLE values greater than 5 for compounds that entered phase II trials and marketed drugs. In our work, several synthesized derivatives had LLE values greater than 2.5 and low logP values (see Supporting Information Figure S1 and S2), thereby suggesting that the pyrazolobenzothiazine chemotype is noteworthy of further investigation.

Another surprising finding was that, although **4a** was the anti-HCV hit compound validated by the strict criteria of the replicon system, curiously this pyrazolobenzothiazine did not rank among the derivatives which exhibited the highest LLE values based on calculations using either K_D or IC_{50} . In contrast, both compound **4e** and **4g** that showed the highest LLE values were not detected as genuine anti-HCV agents in the replicon system. This may be an effect of the higher complexity of the replicon assay compared to the SPR and enzyme inhibition assays. It is influenced by the pharmacokinetic properties of a compound (*e.g.* the ability to enter the cell) and its capability to interact also with a multitude of other cell components. Even though the concept of LLE was originally introduced specifically using pIC_{50} and pK_i presumably to avoid the complication due to the use of cell system, it was later expanded to include pEC_{50} .³⁴ LLE for **4a** using its EC_{50} data determined by RT-PCR assay was 3.21, thus ranging between the LLE values for hit compounds (mean value of 2.5) and lead compounds (mean values of 3.6-3.9).

Additional pyrazolobenzothiazine analogues will have to be explored to identify the features that are associated with high potency in the replicon system and that give higher LLE.

Table 1. Biological results obtained for derivatives **3a**, **4a-j**, **5a**, and **6a**.

cpds	R	R'	SPR on NS5B	NS5B functional assay	Replicon assay on Huh 5-2 cells				LLE (K _D) ^g	LLE (IC ₅₀) ^h
			K _D (μM) ^a	IC ₅₀ (μM) ^b	EC ₅₀ (μM) ^c	EC ₉₀ (μM) ^d	CC ₅₀ (μM) ^e	SI ^f		
3a	3-F	OMe	>300	ND ^{i,j}	172 ± 10	ND ⁱ	>323	2	-	-
4a	3-F	HN-  -NHSO ₂ Me	75±12	21.0±2.8	7.5 ± 2.5	42 ± 2	>370	>49	1.85	2.40
4b	2-F	HN-  -NHSO ₂ Me	162±63	14.2±0.6	6.4 ± 0.2	ND ⁱ	>231	>36	1.61	2.66
4c	4-F	HN-  -NHSO ₂ Me	ND ⁱ	3.9±0.3	23 ± 13	ND ⁱ	>231	>10	-	3.11
4d	H	HN-  -NHSO ₂ Me	53±6	19.8±3.6	14 ± 1	ND ⁱ	>239	>17	2.18	2.61
4e	3-NO ₂	HN-  -NHSO ₂ Me	14±6	ND ^{i,j}	>220	>220	>220	≥1	3.41	-
4f	2-NO ₂	HN-  -NHSO ₂ Me	35±3	20±0.4	17.8 ± 0.1	ND ⁱ	>220	>12.4	2.84	3.09
4g	4-NO ₂	HN-  -NHSO ₂ Me	ND ⁱ	7.7±1.3	7.9 ± 1.0	ND ⁱ	55 ± 8	7.0	-	3.80
4h	3-NH ₂	HN-  -NHSO ₂ Me	163±8	ND ^{i,j}	9.2 ± 0.9	ND ⁱ	20 ± 6	2.2	2.52	-
4i	2-NH ₂	HN-  -NHSO ₂ Me	106±42	39.9±1.7	26 ± 2	ND ⁱ	>232	>9	2.66	3.08
4j	4-NH ₂	HN-  -NHSO ₂ Me	165±16	18.2±2.1	12 ± 1	ND ⁱ	25 ± 5	2	2.53	3.48
5a	3-F	HN-  -NH ₂	161±103	ND ^{i,j}	19 ± 2	ND ⁱ	>270	>14	0.99	-
6a	3-F	O-  -NHSO ₂ Me	63±8	ND ^{i,j}	88 ± 10	ND ⁱ	>185	>2	1.87	-

^a K_D = Dissociation equilibrium constant. At this concentration 50% of all binding site are occupied. Values as averages and standard deviation (SD) from duplicate or triplicate runs. ^b IC₅₀ = concentration of compound that inhibits 50% enzyme activity in vitro. The reported values represent the means ± SD of data derived from two independent experiments performed in duplicate. ^c EC₅₀ = the effective concentration required to inhibit virus induced cytopathic effect by 50%. The reported values represent the means ± SD of data derived at least from three independent experiments. ^d EC₉₀ = the effective concentration required to inhibit virus induced cytopathic effect by 90%. The reported value represents the means ± SD of data derived at least from three independent experiments. ^e CC₅₀ = is the concentration required to reduce the bio-reduction of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) into formazan by 50%. The reported value represents the means ± SD of data derived at least from three independent experiments. ^f SI = selectivity index (ratio of CC₅₀ to EC₅₀). ^g LLE(K_D) = pK_D – predicted logP. ^h LLE(IC₅₀) = pIC₅₀ – predicted logP. ⁱ ND = not determined. ^j Compounds that did not reach the 50% inhibition and show a maximum % inhibition @ 50 μM: **3a** 10.6%, **4e** 33.7%, **4h** 45.8%, **6a** 21.4%, **5a** 31.5%.

Conclusions

Although a wide variety of compounds have been reported as NS5B inhibitors, drugs active against this enzyme have not yet been approved by the FDA. Thus, there is still a compelling need to identify new anti-HCV chemotypes acting on NS5B polymerase. In this context, structure-based virtual screening of our *in-house* library led to the identification of the pyrazolobenzothiazine **3a** as a suitable starting point for the rational design of new potential NS5B inhibitors. A simple synthetic route for novel pyrazolobenzothiazines bearing a *para*-methanesuphonamidephenyl moiety at C-3 position has been developed, leading to the preparation of twelve derivatives. Biochemical and biological testing confirmed that our strategy was successful in the search for a new anti-HCV chemotype most likely targeting the NS5B polymerase. In summary, the results showed that **4a** represented the best hit within this first series of pyrazolobenzothiazines, having relatively good affinity and inhibitory effects in both enzymatic and replicon assays. Further investigations are warranted and are currently in progress to develop pyrazolobenzothiazine derivatives with improved activity and to better elucidate their antiviral mechanism of action.

Experimental section

Molecular Modeling

The crystal structure of NS5B RdRP complexed with inhibitor **2** (PDB ID 3G86) was retrieved from the RCSB Protein Data Bank and used for our modeling studies on PSI. Water molecules, except those involved in mediating hydrogen bonds between the ligands and the protein were deleted. Schrödinger Protein Preparation Wizard,³⁵ a workflow designed to ensure chemical correctness and to optimize a protein structure for further analysis, was then used to obtain a satisfactory starting structure. In particular, hydrogen atoms were added, and bond orders and

charges were assigned; the orientation of hydroxyl groups on Ser, Thr and Tyr, the side chains of Asn and Gln residues, and the protonation state of His residues were optimized. Steric clashes were relieved by performing a small number of minimization steps, not intended to minimize the system completely. In our study, the minimization (OPLS 2500 force field) was stopped when the RMSD of the non-hydrogen atoms reached 0.30 Å.

Docking studies were performed using the software Glide version 5.6.¹⁷ The prepared protein structure was used to generate the receptor grid, which was centered on the crystallographic positions of PSI-NNI **2**.

Prior to docking experiments, the *in-house* library and the designed compounds (**4a-j**, **5a** and **6a**) were built using the Schrödinger Maestro interface³⁶ and then submitted to the LigPrep utility,¹⁶ which rapidly produces low energy 3D structures taking into account ionization states, tautomers, stereochemistries, and ring conformations at the desired pH. For our study, a pH range of 6-8 was set.

The PSI-NNI **2** was instead extracted from the complex with NS5B, and its crystallographic coordinates were transformed in order to avoid biasing the docking toward the known NS5B- bound conformation. After modeling the ligand enolic moiety as anion due to its ionization at physiological pH, the compound was submitted to Polak–Ribiere conjugate gradient minimization [0.0005 kJ/(Å mol) convergence].

All compounds were flexibly docked in a stepwise manner with Glide SP (Standard Precision) and XP (Extra Precision) as scoring functions. Docking experiments were performed using a 0.80 factor to scale the VdW radii of the nonpolar ligand atoms with partial atomic charge less than 0.15 (absolute value). Poses were discarded as duplicates when rms deviation in the ligand-all atoms was less than 1.5 Å and maximum atomic displacement was less than 2.0 Å. Three bound conformations per ligand were retained from SP docking, and these were refined, rescored and minimized using GlideXP. The best XP scoring bound conformation for each ligand was retained. Docking

experiments at PSII (PDB ID 3FQL),²⁰ PSIII (PDB ID 3LKH),^{12b,21} TSI (PDB ID 2BRK)^{12b,22} and TSII (PDB ID 3FRZ)²³ were performed using the same protocol described for PSI.

Figure 2, 3A and 4A were generated using the Ligand Interaction Diagram tool of Maestro GUI,³⁶ whereas Figure 3B and 4B were prepared using the software PyMOL.³⁷

LogP values of the pyrazolobenzothiazines were computed by using Schrödinger QikPro program²⁹ (descriptor QPlogPo/w), and the LLE calculations were performed by using Excel spreadsheet.

Chemistry

All starting materials were commercially available, unless otherwise indicated. Reagents and solvents were purchased from common commercial suppliers and were used as such. Organic solutions were dried over anhydrous Na₂SO₄ and concentrated with a rotary evaporator at low pressure. All reactions were routinely checked by thin-layer chromatography (TLC) on silica gel 60F254 (Merck) and visualized by using UV or iodine. Column chromatography separations were carried out on Merck silica gel 60 (mesh 70-230), flash chromatography on Merck silica gel 60 (mesh 230-400). Melting points were determined in capillary tubes (Büchi Electrothermal model 9100) and are uncorrected. Yields were of purified products and were not optimized. ¹H NMR spectra were recorded at 200 or 400 MHz (Bruker Avance DRX-200 or 400, respectively) while ¹³C NMR spectra were recorded at 100 MHz (Bruker Avance DRX-400) as well as 2D ¹H NMR NOESY run in phase sensitive mode. Chemical shifts are given in ppm (δ) relative to TMS. Spectra were acquired at 298 K. Data processing was performed with standard Bruker software XwinNMR and the spectral data are consistent with the assigned structures. Elemental analyses were performed on a Fisons elemental analyzer, model EA1108CHN, and data for C, H, and N are within 0.4% of the theoretical values.

General procedure for condensation of key intermediate 7 with phenylhydrazines hydrochloride. Method A. To a refluxing solution of key intermediate **7**¹⁹ (1 mmol) in MeOH (20 mL), the appropriate hydrazine hydrochloride (1.2 mmol), dissolved in hot MeOH (2 mL), was added at once. The reaction was maintained at reflux for 3-15 h, then concentrated under reduced pressure to half volume and cooled to room temperature. The precipitated formed was filtered under vacuum to give the pyrazolobenzothiazine-3-carboxymethyl esters **8b-g**, pure by TLC (CHCl₃/MeOH 98:2).

Methyl 1-(2-fluorophenyl)-4-methyl-1,4-dihydropyrazolo[4,3-c][1,2]benzothiazine-3-carboxylate 5,5-dioxide (8b). Following the general procedure method A and using the 2-(fluorophenyl)hydrazine hydrochloride, compound **8b** was obtained in 71% yield (reaction time 5 h) as yellowish crystalline solid: mp 174-175 °C. ¹H NMR (200 MHz, acetone-d₆): δ 3.30 (s, 3H, NCH₃), 4.00 (s, 3H, OCH₃), 7.10 (d, *J* = 7.8 Hz, 1H, H-9), 7.50-7.90 (m, 6H, H-7, H-8, H-3', H-4', H-5' and H-6'), 8.05 (dd, *J* = 1.5 and 7.6 Hz, 1H, H-6).

Methyl 1-(4-fluorophenyl)-4-methyl-1,4-dihydropyrazolo[4,3-c][1,2]benzothiazine-3-carboxylate 5,5-dioxide (8c). Following the general procedure method A and using the 4-(fluorophenyl)hydrazine hydrochloride, compound **8c** was obtained in 86% yield (reaction time 10 h) as white crystalline solid: mp 215-216 °C. ¹H NMR (200 MHz, CDCl₃): δ 3.35 (s, 3H, NCH₃), 4.05 (s, 3H, OCH₃), 7.00 (dd, *J* = 0.7 and 7.8 Hz, 1H, H-9), 7.25-7.35 (m, 2H, H-3' and H-5'), 7.45-7.70 (m, 4H, H-7, H-8, H-2' and H-6'), 8.10 (dd, *J* = 1.4 and 7.8 Hz, 1H, H-6).

Methyl 4-methyl-1-(3-nitrophenyl)-1,4-dihydropyrazolo[4,3-c][1,2]benzothiazine-3-carboxylate 5,5-dioxide (8e). Following the general procedure method A and using the 3-(nitrophenyl)hydrazine hydrochloride, compound **8e** was obtained in 90% yield (reaction time 12 h)

as yellow woolly solid: mp 283-284 °C. ¹H NMR (200 MHz, DMSO-*d*₆): δ 3.20 (s, 3H, NCH₃), 4.00 (s, 3H, OCH₃), 7.15 (d, *J* = 7.6 Hz, 1H, H-9), 7.65 (dt, *J* = 1.5 and 7.9 Hz, 1H, H-8), 7.80 (dt, *J* = 1.5 and 7.9 Hz, 1H, H-7), 7.90 (t, *J* = 8.1 Hz, 1H, H-5'), 8.00-8.10 (m, 2H, H-4' and H-6), 8.45 (t, *J* = 1.9 Hz, 1H, H-2') 8.55 (m, 1H, H-6').

Methyl 4-methyl-1-(2-nitrophenyl)-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxylate 5,5-dioxide (8f). Following the general procedure method A and using the 2-(nitrophenyl)hydrazine hydrochloride (reaction time 15 h); after flash column chromatography purification (CHCl₃/MeOH 99:1), compound **8f** was obtained in 15% yield as yellow woolly solid: mp 277-278 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 3.10 (s, 1H, NCH₃), 3.75 (s, 1H, OCH₃), 6.90 (d, *J* = 7.8 Hz, 1H, H-9), 7.60 (dt, *J* = 1.3 and 7.8 Hz, 1H, H-8), 7.70 (dt, *J* = 1.0 and 7.8 Hz, 1H, H-7), 7.80-7.85 (m, 1H, H-4'), 7.90-8.00 (m, 3H, H-6, H-5' and H-6'), 8.30-8.35 (m, 1H, H-3').

Methyl 4-methyl-1-(4-nitrophenyl)-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxylate 5,5-dioxide (8g). Following the general procedure method A and using the 4-(nitrophenyl)hydrazine hydrochloride, compound **8g** was obtained in 40% yield (reaction time 6 h) as yellow solid: mp 275-276 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 3.10 (s, 3H, NCH₃), 3.90 (s, 3H, OCH₃), 7.10 (d, *J* = 7.8 Hz, 1H, H-9), 7.65 (dt, *J* = 1.3 and 7.8 Hz, 1H, H-8), 7.70 (dt, *J* = 1.1 and 7.8 Hz, 1H, H-7), 7.80-7.85 (m, 2H, H-2' and H-6'), 8.00 (dd, *J* = 1.1 and 7.8 Hz, 1H, H-6), 8.40-8.45 (m, 2H, H-3' and H-5').

General procedure of basic hydrolysis. Method B. A stirred mixture of appropriate pyrazolobenzothiazine methyl esters **3a**,¹⁹ **8b-c**, **8d**,¹⁹ and **8e-g** (1 mmol) in acq. 10% NaOH (6 mL) and MeOH (6 mL) was refluxed for 1 h and then concentrated to one-third of the volume under reduced pressure. The mixture was poured into ice/water and acidified with 2N HCl (pH = 3). The

precipitated formed was then filtered under vacuum, washed with Et₂O and dried to give the pyrazolobenzothiazine-3-carboxylic acids **9a-g** used as it in the next reaction step.

1-(3-Fluorophenyl)-4-methyl-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxylic acid 5,5-dioxide (9a). Following the general procedure method B, compound **9a** was obtained from **3a**,¹⁹ in 88% yield as white solid: mp 243-245 °C. ¹H NMR (200 MHz, acetone-*d*₆): δ 3.30 (s, 3H, NCH₃), 7.20 (dd, *J* = 1.2 and 7.7 Hz, 1H, H-9), 7.45-7.60 (m, 3H, H-7, H-8 and H-6'), 7.65-7.85 (m, 3H, H-2', H-4' and H-5'), 8.05 (dd, *J* = 1.4 and 7.7 Hz, 1H, H-6).

1-(2-Fluorophenyl)-4-methyl-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxylic acid 5,5-dioxide (9b). Following the general procedure method B, compound **9b** was obtained from **8b**, in 89% yield as white solid: mp 224-225 °C. ¹H NMR (200 MHz, acetone-*d*₆): δ 3.30 (s, 3H, NCH₃), 7.10 (d, *J* = 7.3 Hz, 1H, H-9), 7.45-7.95 (m, 6H, H-7, H-8, H-3', H-4', H-5' and H-6'), 8.05 (dd, *J* = 1.4 and 7.7 Hz, 1H, H-6).

1-(4-Fluorophenyl)-4-methyl-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxylic acid 5,5-dioxide (9c). Following the general procedure method B, compound **9c** was obtained from **8c**, in 88% yield as white solid: mp 248-250 °C. ¹H NMR (200 MHz, acetone-*d*₆): δ 3.30 (s, 3H, NCH₃), 7.20 (dd, *J* = 1.0 and 7.5 Hz, 1H, H-9), 7.45-7.55 (m, 2H, H-7 and H-8), 7.60-7.80 (m, 4H, H-2', H-3', H-5' and H-6'), 8.05 (dd, *J* = 1.4 and 7.6 Hz, 1H, H-6).

4-Methyl-1-(3-nitrophenyl)-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxylic acid 5,5-dioxide (9e). Following the general procedure method B, compound **9e** was obtained from **8e**, in 99% yield as yellow solid: mp 184-185 °C. ¹H NMR (200 MHz, DMSO-*d*₆): δ 3.05 (s, 3H, NCH₃), 7.10 (d, *J* = 7.8 Hz, 1H, H-9), 7.65 (dt, *J* = 1.2 and 7.8 Hz, 1H, H-8), 7.75 (dt, *J* = 1.2 and

7.8 Hz, 1H, H-7), 7.90 (t, $J = 8.1$ Hz, 1H, H-5'), 8.00-8.10 (m, 2H, H-6 and H-4'), 8.40 (t, $J = 2.0$ Hz, 1H, H-2'), 8.50 (m, 1H, H-6'), 13.80 (bs, 1H, CO₂H). NMR NOESY spectra showed two relevant NOE cross-peaks: H-9→H-2'; H-9→H-4'.

4-Methyl-1-(2-nitrophenyl)-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxylic acid 5,5-dioxide (9f). Following the general procedure method B, compound **9f** was obtained from **8f**, in 60% yield as yellow solid: mp 220-221 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 3.05 (s, 3H, NCH₃), 6.85 (d, $J = 7.5$ Hz, 1H, H-9), 7.60 (t, $J = 7.5$ Hz, 1H, H-8), 7.70 (t, $J = 7.5$ Hz, 1H, H-7), 7.80 (dd, $J = 2.0$ and 9.0 Hz, 1H, H-6'), 7.85-8.00 (m, 3H, H-6, H-4' and H-5'), 8.30 (dd, $J = 2.1$ and 7.5 Hz, 1H, H-3').

4-Methyl-1-(4-nitrophenyl)-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxylic acid 5,5-dioxide (9g). Following the general procedure method B, compound **9g** was obtained from **8g**, in 98% yield as yellow solid: mp 226-228°C. ¹H NMR (200 MHz, DMSO-*d*₆): δ 3.05 (s, 3H, NCH₃), 7.15 (dd, $J = 1.0$ and 6.7 Hz, 1H, H-9), 7.65-7.80 (m, 2H, H-7 and H-8), 7.85-7.95 (m, 2H, H-2' and H-6'), 8.05 (dd, $J = 1.4$ and 6.9 Hz, 1H, H-6), 8.45-8.55 (m, 2H, H-3' and H-5').

General procedure for amidation reaction with *N*-(4-aminophenyl)methanesulfonamide.
Method C. A mixture of intermediates **9a-g** (1 mmol) in an excess of SOCl₂ was refluxed under stirring for 1 h. The solvent was distilled under reduced pressure and the residues was washed three time with dry benzene. The corresponding pyrazolobenzothiazine-3-carbonyl chloride was immediately dissolved in dry DMF (2 mL) and added dropwise, under nitrogen flux, to a solution of *N*-(4-aminophenyl)methanesulfonamide²⁵ (2 mmol) and Et₃N (2 mmol) in dry DMF (7 mL). The mixture was heated at 40 °C for 24 h. The solvent was then concentrated to half volume and the mixture was poured into ice-water, acidified with 2N HCl (pH = 3) and the precipitated formed was

1
2
3 filtered under vacuum. The solid obtained was crystallized by EtOH/DMF (2:1) to give the target
4
5 pyrazolobenzothiazine-3-carboxamides **4a-g**.
6
7
8

9
10 **1-(3-Fluorophenyl)-4-methyl-N-{4-[(methylsulfonyl)amino]phenyl}-1,4-**
11 **dihydropyrazolo[4,3-c][1,2]benzothiazine-3-carboxamide 5,5-dioxide (4a).** Following the
12 general procedure method C, compound **4a** was obtained from **9a**, in 70% yield as white solid: mp
13 285-287 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 3.00 (s, 3H, SO₂CH₃), 3.15 (s, 3H, NCH₃), 7.05 (d,
14 *J* = 7.6 Hz, 1H, H-9), 7.20-7.25 (m, 2H, H-3" and H-5"), 7.40-7.50 (m, 1H, H-7), 7.55 (dt, *J* = 1.7
15 and 8.5 Hz, 1H, H-8), 7.65-7.80 (m, 6H, H-2', H-4', H-5', H-6', H-2" and H-6"), 8.00 (dd, *J* = 1.1
16 and 6.6 Hz, 1H, H-6), 9.60 (s, 1H, SO₂NH), 10.40 (s, 1H, CONH). ¹³C NMR (100 MHz, DMSO-
17 *d*₆), δ 39.15, 39.36, 113.89 (d, *J*_{C-F} = 20 Hz, C-2'), 117.50 (d, *J*_{C-F} = 20 Hz, C-4'), 121.28, 122.13,
18 122.45 (d, *J*_{C-F} = 2 Hz, C-6'), 123.35, 124.90, 125.16, 126.77, 130.62, 130.74, 130.86, 132.29 (d,
19 *J*_{C-F} = 10 Hz, C-5'), 133.47, 134.70, 135.03, 139.71, 140.52 (d, *J*_{C-F} = 10 Hz, C-1'), 158.72, 162.73
20 (d, *J*_{C-F} = 245 Hz, C-3'). Anal. Calcd (%) for C₂₄H₂₀FN₅O₅S₂: C 53.13, H 3.72, N 12.93. Found C,
21 53.30; H, 3.60; N 12.88.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **1-(2-Fluorophenyl)-4-methyl-N-{4-[(methylsulfonyl)amino]phenyl}-1,4-**
39 **dihydropyrazolo[4,3-c][1,2]benzothiazine-3-carboxamide 5,5-dioxide (4b).** Following the
40 general procedure method C, compound **4b** was obtained from **9b**, in 40% yield as white solid: mp
41 264-266 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 3.00 (s, 3H, SO₂CH₃), 3.30 (s, 3H, NCH₃), 6.95 (d,
42 *J* = 7.7 Hz, 1H, H-9), 7.20-7.25 (m, 2H, H-3" and H-5"), 7.55-7.60 (m, 2H, H-7 and H-8), 7.65-7.80
43 (m, 5H, H-4', H-5', H-6', H-2" and H-6"), 7.95 (t, *J* = 7.8 Hz 1H, H-3'), 8.00 (d, *J* = 7.5 Hz, 1H, H-
44 6), 9.60 (s, 1H, SO₂NH), 10.40 (s, 1H, CONH). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 39.26, 39.38,
45 117.62 (d, *J*_{C-F} = 37 Hz, C-3'), 121.15, 122.08, 123.24, 123.30, 125.22, 126.03, 126.59 (bs, C-6'),
46 127.10 (d, *J*_{C-F} = 20 Hz, C-1'), 129.61 (bs, C-5'), 130.74, 130.89, 131.97, 133.29 (d, *J*_{C-F} = 10 Hz,
47
48
49
50
51
52
53
54
55
56
57
58
59
60

C-4'), 133.71, 134.60, 134.95, 140.31, 156.34 (d, $J_{C-F} = 490$ Hz, C-2'), 158.55. Anal. Calcd (%) for $C_{24}H_{20}FN_5O_5S_2$: C, 53.13; H, 3.72; N, 12.93. Found C, 52.97; H, 3.80; N, 13.01.

1-(4-Fluorophenyl)-4-methyl-N-{4-[(methylsulfonyl)amino]phenyl}-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxamide 5,5-dioxide (4c). Following the general procedure method C, compound **4c** was obtained from **9c**, in 40% yield as white solid: mp 298-300 °C. 1H NMR (400 MHz, DMSO- d_6): δ 3.00 (s, 3H, SO_2CH_3), 3.30 (s, 3H, NCH_3), 7.00 (d, $J = 7.7$ Hz, 1H, H-9), 7.20-7.25 (m, 2H, H-3" and H-5"), 7.45-7.55 (m, 2H, H-7 and H-8), 7.65-7.80 (m, 6H, H-2', H-3', H-5', H-6', H-2" and H-6"), 8.00 (d, $J = 7.5$ Hz, 1H, H-6), 9.60 (s, 1H, SO_2NH), 10.40 (s, 1H, CONH). ^{13}C NMR (100 MHz, DMSO- d_6): δ 39.23, 39.34, 117.50 (d, $J_{C-F} = 20$ Hz, C-3' and C-5'), 121.28, 122.12, 123.45, 124.76, 125.19, 126.51, 128.82 (d, $J_{C-F} = 10$ Hz, C-2' and C-6'), 130.64, 130.76, 130.90, 133.49, 134.65, 135.09, 135.72 (d, $J_{C-F} = 3$ Hz, C-1'), 139.55, 158.80, 162.89 (d, $J_{C-F} = 250$ Hz, C-4'). Anal. Calcd (%) for $C_{24}H_{20}FN_5O_5S_2$: C, 53.13; H, 3.72; N, 12.93. Found C, 53.02; H, 3.86; N, 12.90.

N-{4-[(Methylsulfonyl)amino]phenyl}-1-phenyl-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxamide 5,5-dioxide (4d). Following the general procedure method C, compound **4d** was obtained from **9d**,¹⁹ in 70% yield as pale pink solid: mp 280-283 °C. 1H NMR (400 MHz, DMSO- d_6): δ 3.00 (s, 3H, SO_2CH_3), 3.30 (s, 3H, NCH_3), 6.95 (d, $J = 7.8$ Hz, 1H, H-9), 7.20-7.25 (m, 2H, H-3" and H-5"), 7.65-7.80 (m, 9H, H-7, H-8, H-2', H-3', H-4', H-5', H-2" and H-6"), 8.00 (d, $J = 7.70$ Hz, 1H, H-6), 9.60 (s, 1H, SO_2NH), 10.40 (s, 1H, CONH). ^{13}C NMR (100 MHz, DMSO- d_6): δ 39.26, 39.38, 121.32, 122.15, 123.61, 124.75, 125.20, 126.36, 126.62, 130.57, 130.61, 130.89, 130.92, 133.39, 134.67, 135.14, 139.35, 139.54, 158.89. Anal. Calcd (%) for $C_{24}H_{21}N_5O_5S_2$: C, 55.05; H, 4.04; N, 13.38. Found C, 54.97; H, 3.89; N, 13.61.

***N*-{4-[(Methylsulfonyl)amino]phenyl}-1-(3-nitrophenyl)-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxamide 5,5-dioxide (4e).** Following the general procedure method C, compound **4e** was obtained from **9e**, in 50% yield as white solid: mp 233-235 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 3.00 (s, 3H, SO₂CH₃), 3.30 (s, 3H, NCH₃), 7.05 (d, *J* = 8.0 Hz, 1H, H-9), 7.20-7.25 (m, 2H, H-3" and H-5"), 7.65 (dt, *J* = 1.2 and 8.0 Hz, 1H, H-8), 7.75-7.80 (m, 3H, H-7, H-2" and H-6"), 7.90 (t, *J* = 8.1 Hz, 1H, H-5'), 8.00-8.10 (m, 2H, H-6 and H-6'), 8.50 (m, 1H, H-4'), 8.60 (t, *J* = 2.1 Hz, 1H, H-2'), 9.60 (s, 1H, NHSO₂), 10.50 (s, 1H, NHCO). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 39.05, 39.37, 121.05, 121.28, 122.18, 123.17, 125.01, 125.15, 125.24, 127.11, 130.73, 130.86, 130.90, 131.98, 132.26, 133.53, 134.76, 134.99, 139.86, 140.16, 148.96, 158.63. Anal. Calcd (%) for C₂₄H₂₀N₆O₇S₂: C, 50.70; H, 3.55; N, 14.78. Found C, 51.05; H, 3.52; N, 14.46.

***N*-{4-[(methylsulfonyl)amino]phenyl}-1-(2-nitrophenyl)-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxamide 5,5-dioxide (4f).** Following the general procedure method C, compound **4f** was obtained from **9f**, in 80% yield as white solid: mp 245-247 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 3.00 (s, 3H, SO₂CH₃), 3.25 (s, 3H, NCH₃), 6.95 (d, *J* = 7.8 Hz, 1H, H-9), 7.15-7.20 (m, 2H, H-3" and H-5"), 7.65 (t, *J* = 7.8 Hz, 1H, H-8), 7.70-7.80 (m, 3H, H-7, H-2" and H-6"), 7.90 (d, *J* = 7.7 Hz, 1H, H-6'), 7.95-8.05 (m, 3H, H-6, H-4' and H-5'), 8.40 (d, *J* = 7.6 Hz, 1H, H-3'), 9.55 (s, 1H, NHSO₂), 10.55 (s, 1H, NHCO). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 39.34, 39.35, 121.20, 122.24, 122.84, 124.14, 125.35, 126.39, 126.94, 130.56, 131.04, 131.11, 132.09, 132.17, 132.90, 133.80, 134.73, 134.91, 135.92, 140.50, 145.66, 158.44. Anal. Calcd (%) for C₂₄H₂₀N₆O₇S₂: C, 50.7; H, 3.55; N, 14.78. Found C, 50.40; H, 3.50; N, 15.13.

***N*-{4-[(methylsulfonyl)amino]phenyl}-1-(4-nitrophenyl)-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxamide 5,5-dioxide (4g).** Following the general procedure method C, compound **4g** was obtained from **9g**, in 60% yield as white solid: mp 321-323 °C. ¹H NMR (400

1
2
3 MHz, DMSO- d_6): δ 3.00 (s, 3H, SO₂CH₃), 3.25 (s, 3H, NCH₃), 7.15-7.20 (m, 3H, H-6, H-3" and H-
4 5"), 7.70 (t, J = 7.6 Hz, 1H, H-8), 7.75-7.80 (m, 3H, H-7, H-2" and H-6"), 7.95-8.00 (m, 2H, H-2'
5 and H-6'), 8.10 (d, J = 7.6 Hz, 1H, H-6), 8.45-8.50 (m, 2H, H-3' and H-5'), 9.75 (s, 1H, SO₂NH),
6
7 10.60 (s, 1H, CONH). ¹³C NMR (100 MHz, DMSO- d_6): δ 39.22, 39.31, 121.24, 122.12, 123.19,
8 125.17, 125.51, 125.93, 126.85, 127.46, 130.68, 130.75, 130.93, 133.61, 134.77, 134.96, 140.58,
9 143.82, 147.97, 158.58. Anal. Calcd (%) for C₂₄H₂₀N₆O₇S₂: C, 50.70; H, 3.55; N, 14.78. Found C,
10 50.60; H, 3.50; N 14.93.
11
12
13
14
15
16
17
18
19

20
21 **General procedure for reduction of nitro group. Method D.** A stirred solution of nitro
22 derivatives **4e-g** (1 mmol) in DMF (60 mL) was hydrogenated over a catalytic amount of Raney
23 nickel at room temperature and atmospheric pressure for 5 h. The mixture was then filtered over
24 Celite, the filtrate was evaporated to dryness and the residue was crystallized by EtOH/DMF (2:1)
25 to give the target aminoderivatives **4h-j**.
26
27
28
29
30
31
32
33

34 **1-(3-Aminophenyl)-4-methyl-N-{4-[(methylsulfonyl)amino]phenyl}-1,4-**
35 **dihydropyrazolo[4,3-c][1,2]benzothiazine-3-carboxamide 5,5-dioxide (4h).** Following the
36 general procedure method D, compound **4h** was obtained from **4e**, in 50% yield as whitish solid:
37 mp 266-267 °C. ¹H NMR (400 MHz, CDCl₃): δ 3.00 (s, 3H, SO₂CH₃), 3.30 (s, 3H, NCH₃), 5.80 (s,
38 2H, NH₂), 6.80-6.85 (m, 2H, H-2' and H-4'), 6.85 (d, J = 7.8 Hz, 1H, H-9), 7.10 (d, J = 8.1 Hz, 1H,
39 H-6'), 7.20-7.30 (m, 2H, H-3" and H-5"), 7.30 (t, J = 8.1 Hz, 1H, H-5'), 7.45 (dt, J = 1.1 and 7.8 Hz,
40 1H, H-8), 7.55 (dt, J = 0.8 and 7.8 Hz, 1H, H-7), 7.65-7.70 (m, 2H, H-2" and H-6"), 8.00 (dd, J =
41 1.1 and 7.8 Hz, 1H, H-6), 8.75 (s, 1H, SO₂NH). ¹³C NMR (100 MHz, DMSO- d_6): δ 39.25, 39.33,
42 110.67, 112.61, 115.49, 121.28, 122.12, 123.77, 124.89, 125.01, 126.31, 130.24, 130.46, 130.70,
43 130.80, 133.35, 134.58, 135.15, 138.96, 140.08, 150.73, 158.95. Anal. Calcd for C₂₄H₂₂N₆O₅S₂: C,
44 53.52; H, 4.12; N, 15.60. Found C, 53.39; H, 4.06; N 15.81.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1-(2-Aminophenyl)-4-methyl-N-{4-[(methylsulfonyl)amino]phenyl}-1,4-dihydropyrazolo[4,3-c][1,2]benzothiazine-3-carboxamide 5,5-dioxide (4i). Following the general procedure method D, compound **4i** was obtained from **4f**, in 50% yield as whitish solid: mp 260-262 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 3.00 (s, 3H, SO₂CH₃), 3.25 (s, 3H, NCH₃), 5.50 (s, 2H, NH₂), 6.75 (t, *J* = 8.0 Hz, 1H, H-5'), 6.90-7.15 (m, 3H, H-3', H-6' and H-9), 7.20-7.25 (m, 2H, H-3'' and H-5''), 7.30 (t, *J* = 8.0 Hz, 1H, H-4'), 7.60-7.70 (m, 2H, H-7 and H-8), 7.75-7.80 (m, 2H, H-2'' and H-6''), 8.00 (d, *J* = 7.0 Hz, 1H, H-6), 9.55 (bs, 1H, SO₂NH), 10.50 (s, 1H, CONH). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 39.14, 39.23, 116.67, 116.79, 121.30, 122.13, 123.77, 123.86, 124.04, 124.87, 125.91, 128.55, 130.36, 130.87, 131.01, 131.83, 133.46, 134.62, 135.13, 139.42, 145.61, 158.99. Anal. Calcd for C₂₄H₂₂N₆O₅S₂: C, 53.52; H, 4.12; N, 15.60. Found C, 53.80; H, 4.09; N, 15.35.

1-(4-Aminophenyl)-4-methyl-N-{4-[(methylsulfonyl)amino]phenyl}-1,4-dihydropyrazolo[4,3-c][1,2]benzothiazine-3-carboxamide 5,5-dioxide (4j). Following the general procedure method D, compound **4j** was obtained from **4g**, in 80% yield as whitish solid: mp 198-201 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 3.00 (s, 3H, SO₂CH₃), 3.30 (s, 3H, NCH₃), 5.75 (s, 2H, NH₂), 6.65-6.75 (m, 2H, H-3' and H-5'), 7.05-7.10 (m, 1H, H-9), 7.15-7.25 (m, 4H, H-2', H-6', H-3'' and H-5''), 7.65-7.70 (m, 2H, H-7 and H-8), 7.75-7.80 (m, 2H, H-2'' and H-6'') 7.95-8.00 (m, 1H, H-6), 9.65 (s, 1H, SO₂NH), 10.40 (s, 1H, CONH). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 39.25, 39.51, 114.31, 121.31, 122.09, 124.00, 124.49, 125.04, 125.88, 127.33, 127.43, 130.28, 130.45, 130.83, 133.26, 134.52, 135.22, 138.57, 150.81, 159.03. Anal. Calcd for C₂₄H₂₂N₆O₅S₂: C, 53.52; H, 4.12; N, 15.60. Found C, 53.85; H, 4.14; N, 15.27.

4-[(Methylsulfonyl)amino]phenyl 1-(3-fluorophenyl)-4-methyl-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxylate 5,5-dioxide (6a). Following the general procedure method C and replacing the *N*-(4-aminophenyl)methanesulfonamide²⁵ with the *N*-(4-hydroxyphenyl)methanesulfonamide,²⁶ compound **6a** was obtained from **9a** in 65% yield as white solid: mp 252-254 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 3.00 (s, 3H, SO₂CH₃), 3.30 (s, 3H, NCH₃), 7.00 (d, *J* = 7.7 Hz, 1H, H-9), 7.25-7.30 (m, 4H, H-2", H-3", H-5" and H-6"), 7.40 (dt, *J* = 1.0 and 8.0 Hz, 1H, H-8), 7.50 (dt, *J* = 1.9 and 7.7 Hz, 1H, H-7), 7.55-7.75 (m, 4H, H-2', H-4', H-5', and H-6'), 8.00 (dd, *J* = 1.0 and 7.7 Hz, 1H, H-6), 9.80 (s, 1H, SO₂NH). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 39.07, 39.36, 113.78 (d, *J*_{C-F} = 25 Hz, C-2'), 117.97 (d, *J*_{C-F} = 20 Hz, C-4'), 121.45, 122.50 (bs, C-6'), 123.11, 123.15, 124.91, 125.20, 128.35, 130.80, 130.85, 130.97, 132.52 (d, *J*_{C-F} = 10 Hz, C-5'), 133.65, 135.69, 136.90, 140.40 (d, *J*_{C-F} = 10 Hz, C-1'), 146.46, 159.04, 162.74 (d, *J*_{C-F} = 245 Hz, C-3'). Anal. Calcd (%) for C₂₄H₁₉FN₄O₆S₂: C, 53.13; H, 3.53; N, 10.33. Found C, 53.02; H, 3.50; N, 10.47.

1-(3-Fluorophenyl)-4-methyl-*N*-(4-nitrophenyl)-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxamide 5,5-dioxide (10a). Following the general procedure method C and replacing the *N*-(4-aminophenyl)methanesulfonamide²⁵ with the 4-nitroaniline, compound **10a** was obtained from **9a**, in 35% yield as yellowish solid: mp 265-266 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 3.20 (s, 3H, NCH₃), 7.05 (d, *J* = 7.6 Hz, 1H, H-9), 7.45-7.55 (m, 2H, H-7 and H-8), 7.65-7.75 (m, 4H, H-2', H-4', H-5' and H-6'), 8.00 (dd, *J* = 1.4 and 7.6 Hz, 1H, H-6), 8.05-8.10 (m, 2H, H-2" and H-6"), 8.20-8.25 (m, 2H, H-3" and H-5"), 11.05 (s, 1H, NH).

***N*-(4-aminophenyl)-1-(3-fluorophenyl)-4-methyl-1,4-dihydropyrazolo[4,3-*c*][1,2]benzothiazine-3-carboxamide 5,5-dioxide (5a).** Following the general procedure method D, compound **5a** was obtained from **10a**, in 70% yield as white solid: mp 235-236 °C. ¹H NMR (400

1
2
3 MHz, DMSO-*d*₆): δ 3.15 (s, 3H, NCH₃), 5.00 (s, 2H, NH₂), 6.50-6.55 (m, 2H, H-3" and H-5"), 7.10
4
5 (d, J = 7.4 Hz, 1H, H-9), 7.40-7.50 (m, 3H, H-8, H-2" and H-6"), 7.60 (t, J = 7.7 Hz, 1H, H-7),
6
7 7.65-7.75 (m, 4H, H-2', H-4', H-5' and H-6'), 8.00 (d, J = 7.2 Hz, 1H, H-6), 10.10 (s, 1H, NH). ¹³C
8
9 NMR (100 MHz, DMSO-*d*₆): δ 39.12, 113.76 (d, J_{C-F} = 20 Hz, C-2'), 114.07, 117.40 (d, J_{C-F} = 20
10
11 Hz, C-4'), 122.34 (bs, C-6'), 122.73, 123.44, 124.90, 125.14, 126.56, 127.52, 130.38, 130.65,
12
13 130.82, 132.20 (d, J_{C-F} = 10 Hz, C-5'), 133.43, 140.21, 140.58 (d, J_{C-F} = 10 Hz, C-1'), 146.00,
14
15 158.09, 162.74 (d, J_{C-F} = 245 Hz, C-3'). Anal. Calcd for C₂₄H₁₈FN₅O₃S: C, 59.60; H, 3.91; N, 15.11.
16
17 Found C, 59.87; H, 4.01; N, 14.74.
18
19

20 21 22 23 **Biochemical and biological assays**

24
25 **SPR Interaction analysis.** The analysis of the interaction between the synthesized compounds
26
27 and the ectodomain of HCV NS5B from a Con 1-strain isolate, subtype 1b.³⁸ The C-terminal 21
28
29 amino acid transmembrane region was exchanged for a hexa histidine tag coding sequence.
30
31 Experiments were performed using SPR biosensor analysis with a S51 instrument from Biacore
32
33 (GE Healthcare).
34
35

36
37 The enzyme was immobilized by standard amine coupling to a CM5 biosensor chip. The
38
39 compounds were typically injected over the protein surface for 60 s at 30 μ L/min using in
40
41 concentration series between 6 and 200 μ M in running buffer (20 mM Tris pH 7.4 at room
42
43 temperature, 130 mM NaCl, 0.05 % (v/v) Tween20) to a final DMSO concentration of 5 % (v/v),
44
45 using twofold dilutions. The structural integrity of the immobilized protein was assessed with
46
47 filibuvir (PF-00868554)²³ as a positive control substance. Raw data was processed according to
48
49 standard procedures, including reference and blank subtraction along with solvent correction to
50
51 eliminate any artifacts such as non-specific binding and discrepancies in buffer composition.
52
53 Thereafter, each concentration series was subjected to global non-linear regression in the Biacore
54
55 Evaluation software (GE Healthcare). The 1:1 Langmuir binding model (Eq. 1) was used to
56
57
58
59
60

determine the dissociation equilibrium constant (K_D) and estimate the maximal signal (R_{\max}) from signal versus compound concentrations plots:

$$R_{\text{eq}} = R_{\text{max}} \cdot c/(c + K_D) \quad (\text{Eq. 1})$$

c = compound concentration

NS5B polymerase assay. Recombinant NS5B 1b bearing an N-terminal histidine-tag and 21-amino acid truncation at its C-terminus was purified from the plasmid pThNS5BCΔ21 (NIH1b strain) expressed in *Escherichia coli* DH5α employing Ni-NTA chromatography.³⁰ The compounds were dissolved in dimethylsulfoxide (DMSO) as 10 mM stocks and serially diluted in DMSO immediately prior to the assay. Inhibition of HCV NS5B by the compounds was evaluated by the standard primer dependent elongation assay as previously described.^{13a} Preliminary screening of the was first investigated at 50 μM concentration to identify NS5B inhibitors. Reactions were carried out in a buffer containing 20 mM Tris-HCl (pH 7.0), 100 mM NaCl, 100 mM sodium glutamate, 0.5 mM DTT, 0.01% BSA, 0.01% Tween-20, 5% glycerol, 20 U/mL RNase Out, 0.25 μM poly rA/U12, 20 μM UTP, 1-2 μCi [α -³²P]UTP, 100 ng of NS5BCΔ21 and 1.0 mM MnCl₂ in a total volume of 25 μL. The assay mix was incubated at 30°C for 1 h and stopped by quenching with chilled 5% (v/v) trichloroacetic acid (TCA) supplemented with 0.5 mM pyrophosphate. RNA products were precipitated on GF-B filters and quantified by liquid scintillation counting. NS5B activity in the presence of DMSO control was set at 100% and that in the presence of the compounds was determined relative to this control. Compounds exhibiting ≥50% inhibition at 50 μM concentration were then investigated for their IC₅₀ values. Dose-response curves of 8-12 concentrations of the compounds in duplicate in two independent experiments were plotted using nonlinear regression analysis and IC₅₀ values were determined using Graphpad Prism software.

Cells and viruses. The Huh 5-2 and Huh 9-13 HCV subgenomic replicon-containing cells were provided by Prof R Bartenschlager (University of Heidelberg, Heidelberg, Germany).

Antiviral assays. Huh 5.2 cells, containing the hepatitis C virus genotype 1b I389luc-ubi-neo/NS3-3'/5.1 replicon³⁹ were sub-cultured in DMEM supplemented with 10% FCS, 1% non-essential amino acids, 1% penicillin/streptomycin and 2% Geneticin at a ratio of 1:3 to 1:4, and grown for 3-4 days in 75 cm² tissue culture flasks. One day before addition of the compound, cells were harvested and seeded in assay medium (DMEM, 10% FCS, 1% non-essential amino acids, 1% penicillin/streptomycin) at a density of 6 500 cells/well (100 µL/well) in 96-well tissue culture microtiter plates for evaluation of anti-metabolic effect and CulturPlate (Perkin Elmer) for evaluation of the antiviral effect. The microtiter plates were incubated overnight (37 °C, 5% CO₂, 95-99% relative humidity), yielding a non-confluent cell monolayer.

The evaluation of the anti-metabolic as well as antiviral effect of each compound was performed in parallel. Four-step, 1-to-5 compound dilution series were prepared for the first screen, to collect data for a more detailed dose-response curve, an eight-step, 1-to-2 dilution series was used. Following assay setup, the microtiter plates were incubated for 72 hours (37 °C, 5% CO₂, 95-99% relative humidity). For the evaluation of anti-metabolic effects, the assay medium was aspirated, replaced with 75 µL of a 5% MTS solution in phenol red-free medium and incubated for 1.5 hours (37 °C, 5% CO₂, 95-99% relative humidity). Absorbance was measured at a wavelength of 498 nm (Safire², Tecan), and optical densities (OD values) were converted to percentage of untreated controls. For the evaluation of antiviral effects, assay medium was aspirated and the cell monolayers were washed with PBS. The wash buffer was aspirated, and 25 µL of Glo Lysis Buffer (Promega) was added allowing for cell lysis to proceed for 5 min at room temperature. Subsequently, 50 µL of Luciferase Assay System (Promega) was added, and the luciferase luminescence signal was quantified immediately (1000 ms integration time/well, Safire², Tecan). Relative luminescence units were converted into percentage of untreated controls.

The EC₅₀ and EC₉₀ (values calculated from the dose-response curve) represent the concentrations at which 50% and 90% inhibition, respectively, of viral replication is achieved. The CC₅₀ (value

calculated from the dose-response curve) represents the concentration at which the metabolic activity of the cells is reduced by 50 % as compared to untreated cells.

A concentration of compound is considered to elicit a genuine antiviral effect in the HCV replicon system when the anti-replicon effect is well above the 70% threshold at concentrations where no significant anti-metabolic activity is observed.

Compounds that reproducibly matched the above-outlined selection criteria were evaluated for selective antiviral activity in the Huh 9-13 replicon system. A similar assay setup was used as described above; the antiviral and anti-metabolic effect of the compounds was evaluated in parallel. The anti-metabolic activity of the compounds was quantified as outlined above. For the evaluation of the antiviral effect, assay medium was aspirated and the plates with dry monolayer were stored at -80 °C awaiting extraction. Following thawing of the plates at room temperature, the cell monolayer was lysed with 100 µL of cell-to-cDNA lysis buffer (Invitrogen). Lysis of the cells was allowed to proceed for 10 min at room temperature after which all liquid was transferred to a PCR plate (Axygen). The PCR plate was incubated for 15min at 75 °C (T3, Biometra). The lysate was diluted 1:2 with RNase/DNase-free water, after which 5 µL was transferred to a real-time PCR plate (Applied Biosystems). Replicon RNA content was quantified using a real-time quantitative one-step RT-PCR method (RT-qPCR). Per sample, 20 µL master mix was added containing 12.5 µL 2x RT-qPCR mix (Low Rox One-Step RT-qPCR master mix, Abgene), 0.125 µL of a 60 µM forward primer solution (5'-CCA GAT CAT CCT GAT CGA CCA G-3', final [] of 300 nM), 0.125 µL of a 60 µM reversed primer solution (5'-CCG GCT ACC TGC CCA TTC-3', final [] of 300 nM), 0.3µL of a 5 µM probe solution (5'-ACA TCG CAT CGA GCG AGC ACG TAC-3', final [] of 60 nM) and 6.825 µL of DNase/RNase-free water (ACROS). The samples were analyzed using a SDS7500F (Applied Biosystems, standard thermocycling profile: 30 min at 48 °C, 10 min at 95 °C, 40 cycles of 15 sec at 95 °C and 1 min at 60 °C). Replicon RNA quantities were converted to percentage of untreated controls, allowing to calculate EC₅₀ and EC₉₀ values. Similar as for the Huh

5-2 assay, a compound is only considered to be a selective inhibitor of HCV replication when clear inhibition of virus replication is observed at concentrations that do not elicit a significant anti-metabolic effect on the host cells.

ASSOCIATED CONTENT

Supporting Information

Values of pK_D , pIC_{50} and calculated logP for compounds **4a-j**, **5a**, and **6a**. Plots of calculated logP *versus* pIC_{50} and pK_D . This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Authors

*Phone: +39-075-5855157 (MLB), +39-075-5855126 (GM). Fax: +39-075-5855115. E-mail: lbarreca@unipg.it (MLB), giuseppe.manfroni@unipg.it (GM)

Author Contributions

All authors have given approval to the final version of the manuscript.

Acknowledgements

This work was supported by the Swedish Research Council (VR) to U.H.D and the National Institute of Health Research Grant CA153147 to N.K.-B. We thank Roberto Bianconi, Stijn Delmotte, Mieke Flament and Tom Bellon for excellent technical assistance.

Abbreviation used

BTDZ, hydroxyquinoline-benzothiadiazine; BTZ, hydroxyquinoline-benzothiazine; DAAs, direct-acting antiviral agents; DMEM, Dulbecco's modified Eagle medium; ETF, edge-to-face; FCS, fetal calf serum; HYD, hydrophobic regions; LLE, ligand-lipophilic efficiency; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium; NNIs, non-nucleoside inhibitors; pegIFN- α , pegylated interferon alpha; RdRp, RNA-dependent RNA polymerase; PSI, palm site I; PSII, palm site II; PSIII, palm site III; RBV, ribavirin; SPR, surface plasmon resonance; TSI, thumb site I; TSII, thumb site II.

References and notes

- (1) Sy, T.; Jamal, M. M. Epidemiology of Hepatitis C Virus (HCV) Infection. *Int. J. Med Sci.* **2006**, *3*, 41-46.
- (2) WHO, Factsheet No 164, July 2011. <http://www.who.int/mediacentre/factsheets/fs164/en/>, accessed September 30, 2012.
- (3) Seeff, L. B. Natural History of Chronic Hepatitis C. *Hepatology* **2002**, *36*, S35-S46.
- (4) Scheridan, C. New Merck and Vertex Drugs Raise Standard of Care in Hepatitis C. *Nat. Biotechnol.* **2011**, *29*, 553-554.
- (5) Ferenci, P.; Reddy, K. R. Impact of HCV Protease-Inhibitor-Based Triple Therapy for Chronic HCV Genotype 1 Infection. *Antivir. Ther.* **2011**, *16*, 1187-1201.
- (6) Pawlotsky, J.M.; Chevaliez, S.; McHutchison, J. G. The Hepatitis C Virus Life Cycle as a Target for New Antiviral Therapies. *Gastroenterology* **2007**, *132*, 1979-1998.

- (7) Behrens, S. E.; Tomei, L.; De Francesco, R. Identification and Properties of the RNA-Dependent RNA Polymerase of Hepatitis C Virus. *EMBO J.* **1996**, *15*, 12-22.
- (8) Wu, J. Z.; Hong, Z. Targeting NS5B RNA-Dependent RNA Polymerase for Anti-HCV Chemotherapy. *Curr. Drug Targets Infect. Disord.* **2003**, *3*, 207-219.
- (9) Sofia, M. J.; Chang, W.; Furman, P.A.; Mosley, R. T.; Ross, B. S. Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase. *J. Med. Chem.* **2012**, *55*, 2481-2531.
- (10) Mayhoub, A. S. Hepatitis C RNA-Dependent RNA Polymerase Inhibitors: a Review of Structure-Activity and Resistance Relationships; Different Scaffolds and Mutations. *Bioorg. Med. Chem.* **2012**, *20*, 3150-3161.
- (11) Barreca, M. L.; Iraci, N.; Manfroni, G.; Cecchetti, V. Allosteric Inhibition of the Hepatitis C Virus NS5B Polymerase: in Silico Strategies for Drug Discovery and Development. *Future Med. Chem.* **2011**, *3*, 1027-1055.
- (12) a) Manfroni, G.; Paeshuyse, J.; Massari, S.; Zanolli, S.; Gatto, B.; Maga, G.; Tabarrini, O.; Cecchetti, V.; Fravolini, A.; Neyts, J. Inhibition of Subgenomic Hepatitis C Virus RNA Replication by Acridone Derivatives: Identification of an NS3 Helicase Inhibitor. *J. Med. Chem.* **2009**, *52*, 3354-3365. b) Manfroni, G.; Meschini, F.; Barreca, M. L.; Leyssen, P.; Samuele, A.; Iraci, N.; Sabatini, S.; Massari, S.; Maga, G.; Neyts, J.; Cecchetti, V. Pyridobenzothiazole Derivatives as New Chemotype Targeting the HCV NS5B Polymerase. *Bioorg. Med. Chem.* **2012**, *20*, 866-876.
- (13) a) Nichols, D. B.; Fournet, G.; Gurukumar, K. R. ; Basu, A.; Lee, J. C.; Sakamoto, N.; Kozielskie, F.; Musmuca, I.; Joseph, B.; Ragno, R.; Kaushik-Basu, N. Inhibition of Hepatitis C Virus NS5B Polymerase by S-Trityl-L-Cysteine Derivatives. *Eur. J. Med. Chem.* **2012**, *49*, 191-199. b) Musmuca, I.; Caroli, A.; Mai, A.; Kaushik-Basu, N.; Arora, P.; Ragno, R. Combining 3-D Quantitative Structure-activity Relationship with Ligand Based and Structure-based

- Alignment Procedures for in Silico Screening of New Hepatitis C virus NS5B Polymerase Inhibitors. *J. Chem. Inf. Model.* **2010**, *50*, 662-676.
- (14) Das, D.; Hong, J.; Chen, S. H.; Wang, G.; Beigelman, L.; Seiwert, S. D. Buckman, B. O. Recent Advances in Drug Discovery of Benzothiadiazine and Related Analogs as HCV NS5B Polymerase Inhibitors. *Bioorg. Med. Chem.* **2011**, *19*, 4690-4703.
- (15) de Vicente, J.; Hendricks, R. T.; Smith, D. B.; Fell, J. B.; Fischer, J.; Spencer, S. R.; Stengel, P. J.; Mohr, P.; Robinson, J. E.; Blake, J. F.; Hilgenkamp, R. K.; Yee, C.; Adjabeng G.; Elworthy, T. R.; Tracy, J.; Chin, E.; Li, J.; Wang, B.; Bamberg, J. T.; Stephenson, R.; Oshiro, C.; Harris, S. F.; Ghate, M.; Leveque, V.; Najera, I.; Le Pogam, S.; Rajyaguru, S.; Ao-Ieong, G.; Alexandrova, L.; Larrabee, S.; Brandl, M.; Briggs, A.; Sukhtankar, S.; Farrell, R.; Xu, B. Non-Nucleoside Inhibitors of HCV Polymerase NS5B. Part 2: Synthesis and Structure-Activity Relationships of Benzothiazine-Substituted Quinolinediones. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 3642-3646.
- (16) LigPrep, version 2.5, Schrödinger, LLC, New York, NY, 2011.
- (17) a) Glide, version 5.6, Schrödinger, LLC, New York, NY, 2010. b) Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shaw, D. E.; Shelley, M.; Perry, J. K.; Francis, P.; Shenkin, P. S. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. *J. Med. Chem.* **2004**, *47*, 1739-1749. c) Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. *J. Med. Chem.* **2004**, *47*, 1750-1759. d) Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes. *J. Med. Chem.* **2006**, *49*, 6177-6196.

- (18) The synthesis of compound **3a** has been reported previously by us (see ref. 19). Compound **3a** was re-synthesized and its identity was verified by ^1H and ^{13}C NMR; the purity was determined by combustion analysis and was found to be >95%. Compound **3a**: ^1H NMR (400 MHz, CDCl_3): δ 3.27 (s, 3H, NCH_3), 4.00 (s, 3H, OCH_3), 7.05 (d, $J = 8.0$ Hz, 1H, H-9), 7.20-7.30 (m, 1H, H-2'), 7.35-7.40 (m, 2H, H-4' and H-5'), 7.45-7.55 (m, 2H, H-8 and H-6'), 7.65 (t, $J = 8.0$ Hz, 1H, H-7), 8.05 (dd, $J = 0.9$ and 7.9 Hz, 1H, H-6). ^{13}C NMR (100 MHz, CDCl_3): δ 38.81, 52.63, 113.31 (d, $J_{\text{C-F}} = 20$ Hz, C-2'), 117.01 (d, $J_{\text{C-F}} = 20$ Hz, C-4'), 121.24 (d, $J_{\text{C-F}} = 3.4$ Hz, C-6'), 123.418, 124.36, 125.15, 128.27, 129.72, 130.44, 131.17 (d, $J_{\text{C-F}} = 8.9$ Hz, C-5'), 131.34, 132.21, 136.72, 140.32 (d, $J_{\text{C-F}} = 10$ Hz, C-1'), 160.81, 162.88 (d, $J_{\text{C-F}} = 249$ Hz, C-3'). Anal. Calcd for $\text{C}_{18}\text{H}_{14}\text{FN}_3\text{O}_4\text{S}$: C, 55.81; H, 3.64; N, 10.85. Found C, 55.92; H, 3.76; N, 10.65.
- (19) Cecchetti, V.; Fravolini, A.; Schiaffella, F.; De Regis, M.; Orzalesi, G.; Volpato, I. Synthesis and Pharmacological Activity of Pyrazolo-1,2-benzothiazine- and Isoxazolo-1,2-benzothiazinecarboxamides. *Il Farmaco* **1983**, 38, 35-44.
- (20) Hang, J. Q.; Yang, Y.; Harris, S. F.; Leveque, V.; Whittington, H. J.; Rajyaguru, S.; Ao-Ieong, G.; McCown, M. F.; Wong, A.; Giannetti, A. M.; Le Pogam, S.; Talamás, F.; Cammack, N.; Nájera, I.; Klumpp, K. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus. *J. Biol. Chem.* **2009**, 284, 15517-15529.
- (21) Cheng, C. C.; Shipps, G. W. Jr.; Yang, Z.; Kawahata, N.; Lesburg, C. A.; Duca, J. S.; Bandouveres, J.; Bracken, J. D.; Jiang, C. K.; Agrawal, S.; Ferrari, E.; Huang, H. C. Inhibitors of Hepatitis C Virus Polymerase: Synthesis and Characterization of Novel 2-oxy-6-Fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides. *Bioorg. Med. Chem. Letters* **2010**, 20, 2119-2124.
- (22) Di Marco, S.; Volpari, C.; Tomei, L.; Altamura, S.; Harper, S.; Narjes, F.; Koch, U.; Rowley, M.; De Francesco, R.; Migliaccio, G.; Carfi, A. Interdomain Communication in

- Hepatitis C Virus Polymerase Abolished by Small Molecule Inhibitors Bound to a Novel Allosteric Site. *J. Biol. Chem.* **2005**, *280*, 29765-29770
- (23) Li, H.; Tatlock, J.; Linton, A.; Gonzalez, J.; Jewell, T.; Patel, L.; Ludlum, S.; Drowns, M.; Rahavendran, S. V.; Skor, H.; Hunter, R.; Shi, S. T.; Herlihy, K.J.; Parge, H.; Hickey, M.; Yu, X.; Chau, F.; Nonomiya, J.; Lewis C. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a Potent and Orally Available Hepatitis C Virus Polymerase Inhibitor. *J. Med. Chem.* **2009**, *52*, 1255-1258.
- (24) Sabatini, S.; Gosetto, F.; Seritella, S.; Manfroni, G.; Tabarrini, O.; Iraci, N.; Brincat, J. P.; Carosati, E.; Villarini, M.; Kaatz, G. W.; Cecchetti, V. Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a Promising New Class of Staphylococcus Aureus NorA Efflux Pump Inhibitors. *J. Med. Chem.* **2012**, *55*, 3568-3572.
- (25) Waslei, J.; Rosenthal, G. J.; Sun, X.; Strong, S.; Qiu, J. Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents. PTC WO 2010/019903 A1, 2010.
- (26) Wang, Y.; Guziec, F. S. A Convenient Reductive Deamination (Hidrodeamination) of Aromatic Amines. *J. Org. Chem.* **2001**, *66*, 8293-8296.
- (27) a) Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand Efficiency: a Useful Metric for Lead Selection. *Drug Discov. Today* **2004**, *9*, 430-431; b) Reynolds, C. H.; Tounge B. A.; Bembenek, S. D. Ligand Binding Efficiency: Trends, Physical basis, and Implications. *J. Med. Chem.* **2008**, *51*, 2432-2438.
- (28) Leeson, P. D.; Springthorpe, B. The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry. *Nat. Rev. Drug Discov.* **2007**, *6*, 881-890.
- (29) QikPro, version 3.5, Schrödinger, LLC, New York, NY, 2012.
- (30) a) Kaushik-Basu, N.; Bopda-Waffo, A.; Talele, T. T.; Basu, A.; Costa, P. R.; da Silva, A. J.; Sarafianos, S. G.; Noel, F. Identification and Characterization of Coumestans as Novel HCV

- NS5B Polymerase Inhibitors. *Nucleic Acids Res.* **2008**, *36*, 1482-1496. b) Chen, Y.; Bopda-Waffo, A.; Basu, A.; Krishnan, R.; Silberstein, E.; Taylor, D. R.; Talele, T. T.; Arora, P.; Kaushik-Basu, N. Characterization of Aurintricarboxylic Acid as a Potent Hepatitis C Virus Replicase Inhibitor. *Antivir. Chem. Chemother.* **2009**, *20*, 19-36.
- (31) Compound **1** was synthesized by us following the experimental procedure reported in ref. 32. Its identity was verified by ^1H NMR; the purity was determined by combustion analysis and was found to be >95%. Compound **1**: ^1H NMR (400 MHz, CDCl_3): δ 1.00 (d, $J = 6.5$ Hz, 6H, CH_3), 1.55-1.65 (m, 2H, CH_2), 1.85 (spt, $J = 6.5$ Hz, 1H CH), 4.30-4.40 (m, 2H, NCH_2), 7.30-7.50 (m, 4H, Ar-H), 7.60-7.80 (m, 2H, Ar-H), 8.00 (dd, $J = 0.8$ and 7.9 Hz, 1H, Ar-H), 8.30 (dd, $J = 1.6$ and 8.1 Hz, 1H, Ar-H), 14.50 (bs, 1H, NH), 15.10 (s, 1H, OH). Anal. Calcd for $\text{C}_{21}\text{H}_{21}\text{N}_3\text{O}_4\text{S} \cdot 0.3 \text{ EtOAc}$: C, 60.85; H, 5.41; N, 9.53. Found C, 61.25; H, 5.14; N, 9.15.
- (32) Tedesco, R.; Shaw, A. N.; Bambal, R.; Chai, D.; Concha, N. O.; Darcy, M. G.; Dhanak, D.; Fitch, D.M.; Gates, A.; Gerhardt, W. G.; Halegoua, D. L.; Han, C.; Hofmann, G. A.; Johnston, V. K.; Kaura, A. C.; Liu, N.; Keenan, R. M.; Lin-Goerke, J.; Sarisky, R. T.; Wiggall, K. J.; Zimmerman, M. N.; Duffy, K. J. 3-(1,1-Dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, Potent Inhibitors of Hepatitis C Virus RNA-dependent RNA Polymerase. *J. Med. Chem.* **2006**, *49*, 971-983.
- (33) Tarcsay, A.; Nyíri, K.; Keseru, G. M. Impact of Lipophilic Efficiency on Compound Quality. *J. Med. Chem.* **2012**, *55*, 1252-1260.
- (34) a) Christiansen, E.; Due-Hansen, M. E.; Urban, C.; Grundmann, M.; Schröder, R.; Hudson, B. D.; Milligan, G.; Cawthorne, M. A.; Kostenis, E.; Kassack, M. U.; Ulven, T. Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonists: Methylpropoxy Appendage Lowers Lipophilicity and Improves ADME Properties. *J. Med. Chem.* **2012**, *55*, 6624-6628. b) Cid, J. M.; Tresadern, G.; Vega, J. A.; de Lucas, A. I.; Matesanz, E.; Iturrino, L.; Linares, M. L.; Garcia, A.; Andrés, J. I.; Macdonald, G. J.; Oehlrich, D.; Lavreysen, H.; Megens, A.; Ahnaou, A.; Drinkenburg, W.;

- Mackie, C.; Pype, S.; Gallacher, D.; Trabanco, A. A. Discovery of 3-Cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor. *J. Med. Chem.* **2012**, *55*, 8770-8789.
- (35) Schrödinger Suite 2011; Epik version 2.2, Schrödinger, LLC, New York, NY, 2011; Impact version 5.7, Schrödinger, LLC, New York, NY, 2011; Prime version 2.3, Schrödinger, LLC, New York, NY, 2011.
- (36) Maestro, version 9.2, Schrödinger, LLC, New York, NY, 2011.
- (37) The PyMOL Molecular Graphics System, Version 1.5.0.4, Schrödinger, LLC.
- (38) Winkvist, J.; Abdurakhmanov, E.; Baraznenok, V.; Henderson, I.; Vrang, L.; Danielson, U. H. Resolution of the Interaction Mechanisms and Characteristics of Non-nucleoside Inhibitors of Hepatitis C Virus Polymerase. *Antivir. Res.* Doi: S0166-3542(12)00318-X.10.1016/j.antiviral.2012.12.027.
- (39) Vrolijk, J. M.; Kaul A.; Hansen, B. E.; Lohmann, V.; Haagmans B. L.; Schalm S. W.; Bartenschlager, R. A Replicon-Based Bioassay for the Measurement of Interferons in Patients with Chronic Hepatitis C. *J. Virol. Methods* **2003**, *110*, 201-209.

Table of Contents graphic

